AQST Q3 2023 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$13M+13.4% YoY

Gross Profit

$8M63.1% margin

Operating Income

-$2M-18.3% margin

Net Income

-$2M-15.7% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$774,000

Balance Sheet

Total Assets

$59M

Total Liabilities

$162M

Stockholders' Equity

-$103M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$11M	+13.4%
Gross Profit	$8M	$7M	+20.0%
Operating Income	-$2M	-$9M	+73.2%
Net Income	-$2M	-$13M	+83.8%

Revenue Segments

Manufacture and Supply Revenue

$11M88%

License and Royalty Revenue

$1M8%

Co-Development and Research Fees

$490,0004%

Geographic Segments

UNITED STATES

$10M76%

Non-US

$3M24%